Clinical trials: Lenalidomide
Non-Hodgkin Lymphoma
Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
This is a randomized, open label, multicenter phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of…
- Trial name
- BELINDA (NCT03570892)
- Testing
- Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy, Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
- Where
- 67 sites in United States, Australia and 16 more
- Volunteers
- 330 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma
The study evaluated the safety of Lenalidomide monotherapy in participants with advanced multiple myeloma who had discontinued treatment with combination thalidomide plus high-dose dexamethasone or high-dose dexamethasone alone…
- Trial name
- NCT00622336
- Testing
- CC-5013, Lenalidomide
- Where
- 7 sites in Russia, Ukraine
- Volunteers
- 330 people
- Sponsor
- Celgene
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
This phase I/II trial studies the side effects and best dose of lenalidomide when given together with rituximab-ifosfamide-carboplatin-etoposide (R-ICE) and to see how well they work in treating patients with diffuse large B-cell…
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma
- Trial name
- NCT02628405
- Testing
- Carboplatin, Etoposide, Ifosfamide
- Where
- 12 sites in United States
- Volunteers
- 30 people
- Sponsor
- Academic and Community Cancer Research United
Multiple Myeloma, Triple Negative Breast Cancer
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
This study is comprised of a main study, an observational study, and optional survey studies. The main study is being done to see whether using Duffy null specific treatment dosing guidelines can reduce or delay dose…
- Conditions
- Multiple Myeloma, Triple Negative Breast Cancer, Duffy Blood Group, Chemokine Receptor Gene Mutation, Duffy Blood Group, Chemokine Receptor Gene C.-67T>C
- Trial name
- NCT07341867
- Testing
- Dexamethasone, Bortezomib, LENALIDOMIDE
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Andrew Hantel, MD
Metastatic Prostate Cancer
A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer
Background: Prednisone and docetaxel have been used successfully in treating patients with prostate cancer, either when used alone or in combination with other agents.
- Trial name
- NCT00942578
- Testing
- Bevacizumab, Lenalidomide, Docetaxel
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
This is a national, multicenter, open-label, randomized, comparative study designed to compare, first, the TTP of the two treatment schemes proposed (MPV followed by Rd or MPV alternating with Rd) in newly diagnosed MM patients…
- Trial name
- NCT01237249
- Testing
- Melphalan, Prednisone, Velcade
- Where
- 63 sites in Spain
- Volunteers
- 250 people
- Sponsor
- PETHEMA Foundation
Multiple Myeloma
Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma
The purpose of the study is to determine the safety and efficacy of the use of bendamustine in combination with a commonly used combination chemotherapy to treat relapsed and refractory multiple myeloma.
- Trial name
- BVRD (NCT01484626)
- Testing
- Bendamustine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Loyola University
Ovarian Cancer
Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
Phase I will determine the MTD and evaluated the safety profile of oral lenalidomide on days 1-21 when given with liposomal doxorubicin on day 1 of every 28 day cycle Phase II will commence once the MTD is established, additional…
- Trial name
- NCT00179725
- Testing
- CC-5013, liposomal doxorubicin
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Celgene Corporation
Multiple Myeloma
2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy
This study will compare the effectiveness and safety of maintenance therapy with continuous bortezomib, lenalidomide, and dexamethasone (VRD) compared to maintenance therapy that alternates VRD with Elotuzumab, lenalidomide, and…
- Trial name
- NCT03000634
- Testing
- Elotuzumab, Bortezomib, Lenalidomide
- Sponsor
- University of Arkansas
Marginal Zone Lymphoma
Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)
This study aims to evaluate real-world treatment modalities and their corresponding effectiveness and safety in Chinese patients with marginal zone lymphoma, while also exploratively analyzing patient characteristics and…
- Trial name
- MOTIVE (NCT06534463)
- Testing
- All treatment regimen selections and usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Ruijin Hospital
Multiple Myeloma
A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation
The purpose of this study is to test any good and bad effects of giving a combination of study drugs before and after autologous stem cell transplant.
- Trial name
- NCT03556332
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone
- Where
- 12 sites in United States
- Volunteers
- 41 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Myeloma
Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)
The goal of this clinical research study is to find the highest tolerable dose of Siltuximab that can be given in combination with Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone to patients with MM.
- Trial name
- NCT01531998
- Testing
- Lenalidomide, Bortezomib, Siltuximab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Follicular Lymphoma
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study
This study is planned to prospectively observe and verify the efficacy and safety of induction therapy with obinutuzumab in combination with lenalidomide followed by maintenance therapy with obinutuzumab and lenalidomide in…
- Trial name
- NCT05846763
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
POEMS Syndrome
The Treatment of Lenalidomide in Patients With POEMS Syndrome
Lenalidomide is a immunomodulatory drug derived from thalidomide, without neurotoxicity. Lenalidomide blocks the increased secretion of interleukin-6, tumor necrosis factor alpha and vascular endothelial growth factor (VEGF).
- Trial name
- NCT00971685
- Testing
- Lenalidomide and dexamethasone
- Where
- Italy
- Volunteers
- 16 people
- Sponsor
- Istituto Clinico Humanitas
Multiple Myeloma
Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)
Lenalidomide is a standard of care for maintenance therapy after autologous stem cell transplantation in newly diagnosed myeloma patients.
- Trial name
- IFM 2024_06 (NCT06931704)
- Testing
- Elranatamab, Daratumumab, Lenalidomide
- Where
- 36 sites in France
- Volunteers
- 176 people
- Sponsor
- Nantes University Hospital
T-cell Lymphoma
A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma
T-cell Non-Hodgkin's lymphomas are a group of cancers that are usually treated with chemotherapy, radiation therapy, or occasionally surgery. T-cell lymphomas are relatively uncommon and therefore not well studied.
- Trial name
- NCT00322985
- Testing
- Lenalidomide
- Where
- 5 sites in Canada
- Volunteers
- 40 people
- Sponsor
- AHS Cancer Control Alberta
Acute Myeloid Leukemia
Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients
The purpose of this study is to determine if Revlimid will help maintain patients with acute myeloid leukemia in remission.
- Trial name
- NCT00957385
- Testing
- Revlimid
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- University Health Network, Toronto
Relapsed Neuroblastoma
DNA Vaccination Against Neuroblastoma
This is pilot open-label study to evaluate the safety and immunogenicity of a DNA vaccine strategy in relapsed neuroblastoma patients following chemotherapy and HSC transplantation.
- Trial name
- NCT04049864
- Testing
- DNA vaccine, Salmonella oral vaccine, Lenalidomide
- Where
- Belarus
- Volunteers
- 12 people
- Sponsor
- Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Multiple Myeloma
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by…
- Trial name
- CARTITUDE-5 (NCT04923893)
- Testing
- Bortezomib, Dexamethasone, Lenalidomide
- Where
- 136 sites in United States, Argentina and 24 more
- Volunteers
- 743 people
- Sponsor
- Janssen Research & Development, LLC
Leukemia, Lymphoid, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia
The study objectives are to evaluate the safety and efficacy of the oral administration of lenalidomide in combination with dexamethasone in the treatment of adult patients with refractory or relapsed non-Ph+ B-cell lineage acute…
- Trial name
- RV-405 LAL (NCT01116193)
- Testing
- Lenalidomide plus dexamethasone
- Where
- 4 sites in France
- Volunteers
- 10 people
- Sponsor
- Institut de Cancérologie de la Loire
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.